within Pharmacolibrary.Drugs.ATC.P;

model P01AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.058333333333333334,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ornidazole is a nitroimidazole antimicrobial agent, structurally related to metronidazole, primarily used for the treatment of infections caused by anaerobic bacteria and protozoa such as giardiasis, amoebiasis, and trichomoniasis. It is used in several countries, particularly India and other non-US markets, and is not approved by the FDA in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adults (sex not specified), after single oral administration.</p><h4>References</h4><ol><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936050-00004&quot;>10.2165/00003088-199936050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10384859/&quot;>https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Zhang, C, et al., &amp; Liu, D (2019). Mucoadhesive buccal film containing ornidazole and dexamethasone for oral ulcers: in vitro and in vivo studies. <i>Pharmaceutical development and technology</i> 24(1) 118–126. DOI:<a href=&quot;https://doi.org/10.1080/10837450.2018.1428814&quot;>10.1080/10837450.2018.1428814</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29334299/&quot;>https://pubmed.ncbi.nlm.nih.gov/29334299</a></p></li><li><p>Kumar, YS, et al., &amp; Paradkar, AR (2007). Effect of rifampicin pretreatment on the transport across rat intestine and oral pharmacokinetics of ornidazole in healthy human volunteers. <i>Drug metabolism and drug interactions</i> 22(2-3) 151–163. DOI:<a href=&quot;https://doi.org/10.1515/dmdi.2007.22.2-3.151&quot;>10.1515/dmdi.2007.22.2-3.151</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17708065/&quot;>https://pubmed.ncbi.nlm.nih.gov/17708065</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01AB03;
